A preliminary study on MTDH expression as a potential prognostic cancer marker by Kaminska, Katarzyna et al.
211www.journals.viamedica.pl/medical_research_journal
ORIGINAL ARTICLE
Katarzyna Kaminska1, Sylwia Szablewska2, Krzysztof Roszkowski2*, Marzena Anna Lewandowska3 
1Molecular Oncology and Genetics Department, Innovative Medical Forum, The F. Lukaszczyk Oncology Center Bydgoszcz, Poland 
2Department of Oncology, Radiotherapy and Gynecologic Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz,  
Poland
3Department of Thoracic Surgery and Tumors, Faculty of Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 
A preliminary study on MTDH expression 
as a potential prognostic cancer marker
ABSTRACT
Background: Clinical studies have revealed that MTDH is overexpressed in various malignancies and 
is associated with disease progression and poor clinical outcomes. In order to study MTDH prognostic 
potential, we decided to evaluate MTDH expression changes using cancerous and non-cancerous cells 
lines. Secondly, for the first time, we evaluated MTDH expression in prostate cancer cell lines representing 
different metastatic potential in vivo.
Methods: MTDH and PBGD (control) genes expression were measured by reverse transcription-quantitative 
polymerase chain reaction assay using Universal Probe Library in cancerous and non-cancerous cell lines. 
Results: MTDH gene expression analysis showed a decrease in colorectal cancer cell lines (Caco2, HT29) 
compared to non-cancerous cells lines (VH10, VH25, Hek293). The mean level of the MTDH mRNA ex-
pression, normalized in relation to the reference gene PBGD, increased in the prostate cancer cell lines 
as follows: PC3 (0.62 ± 0.07), PC3M (1.02 ± 0.17), PC3MPro4 (1.20 ± 0.22), and reached the highest 
value in PC3M4 (1.86 ± 0.48). In VH10, the expression of this gene was at 1.0 ± 0.07.
Conclusions: Our MTDH gene expression data are consistent with Mtdh protein expression analyzed in 
The Human Protein Atlas (HPA). Increasing MTDH expression is a promising prognostic factor. 
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Introduction
Bioinformatics analysis of pharmacogenetic (60 cell 
lines, including 58 cancer lines, with a specific cytoge-
netic profile and the gene expression profile, tested 
for the resistance or sensitivity to the 24,000 new 
chemicals) identified the 8q22 region as potentially 
associated with response to chemotherapy [1]. Stud-
ies using high-throughput technologies allowed the 
characterization of the high correlation between the 
amplification of genes on chromosome 8q22 and early 
recurrence of cancer [2–4]. 
There are 13 known genes in that region of chro-
mosome, including MTDH which plays a key role in the 
metastasis [4]. Interestingly, MTDH has 30–40% higher 
expression in breast cancer what accelerates the for-
mation of metastasis and increases chemoresistance 
[4]. The MTDH gene was first identified in PHFA cells 
(Primary Human Fetal Astrocytes) after inducing with 
HIV-1 (Human Immunodeficiency Virus-1) or exposure 
to HIV-1 envelope glycoprotein [5, 6]. 
MTDH (Metadherin) firstly called AEG-1 (Astrocyte 
Elevated Gene-1), then LYRIC (3D3 and LYsine-RIch 
CEACAM1 co-isolated) is a gene that encodes a protein 
involved in physiological processes, such as regulating 
differentiation and proliferation of progenitor cells at 
early stages of embryonic development as part of the 
RNA-induced silencing complex (RISC) that participates 
in gene silencing. However, the protein is also involved 
in some pathological conditions, including cancer 
metastasis, increased proliferation and multidrug re-
sistance [7–9]. 
Recently, clinical studies have revealed that MTDH is 
overexpressed in various cancers and associated with 
disease progression and poor clinical outcomes [10]. 
Moreover, MTDH has been found to promote cancer 
metastasis, chemoresistance, invasion, angiogenesis 
[7–9] and a key player in radioresistance regulation [11].
In this study, we analyzed the expression of the 
MTDH gene in the cancerous and noncancerous 
cells. Moreover, we decided to check how the ex-
pression of MTDH changes with the advancement of 
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prostate cancer. For this purpose, we used a research 
model of cell lines derived from the PC3 line: PC3M, 
PC3MLN4 and PC3MPro4 ref: Pettaway CA, Pathak S, 
1996 https://www.ncbi.nlm.nih.gov/pubmed/9816342), 
which present various degrees of advancement of the 
same cancer.
Methods
Cell line cultures
The PC3, PC3M, PC3MLN4 and PC3MPro4 cell lines 
[12] were cultured in the RPMI medium, while the VH10, 
CACO2, HT29 and Hek293 cell lines were cultured in 
the DMEM medium (both from BioWest SAS (France) 
with 10% fetal bovine serum (FBS) (Pan-Biotech GmbH, 
Germany) and a 5% antibiotic and antimycotic solution 
(BioWest SAS) at 37°C in a 5% CO2 atmosphere at 
a constant humidity. 
mRNA isolation
mRNA isolation was performed using the High 
Pure RNA Isolation Kit from Roche Diagnostics GmbH 
(Germany) according to the manufacturer’s protocol. 
The method includes lysis of cells and subsequent 
separation of RNA on silica columns. RNA from each 
cell line was isolated in triplicate.
Reverse transcription reaction
cDNA synthesis was carried out using the Tran-
scriptor High Fidelity kit cDNA Synthesis Kit from Roche 
Diagnostics GmbH according to the manufacturer’s 
protocol, using two types of primers: Anchored oligo 
(dT) 18 Primer and Random Hexamer Primer.
Real-Time PCR
Real-time PCR was carried out using primers with 
the following sequences: reverse primer 5’-gaaactggct-
cagcagtagacc -3’; forward primer 5’- actggagatgcta-
atacaaatgga -3 ‘, and the TaqMan UPL 60 probe. The 
primers were selected using the free Universal Probe 
Library Assay Design Center application available online 
at www.universalprobelibrary.com. The porphobilino-
gen deaminase (PBGD) gene (Universal Probe Library 
Human PBGD Gene Assay, Roche, Life Science) was 
used as a reference gene for the normalization of the ob-
tained data. The real-time PCR reaction was performed 
using Light Cycler 2.0 PCR System Roche Diagnostics 
GmbH (Germany) in the following conditions: one cycle 
at 95°C/10 min; 45 cycles of denaturation (95°C/10 sec), 
annealing (60°C/30 sec) and extension (72°C/1 sec) with 
data collection in two channels: 530 nm for FAM and 
Figure 1. Results of the MTDH gene expression. Analyses 
were performed three times in three biological replicates 
(9 repetitions in total) and results were normalized with 
PBGD as the reference gene. The graph presents cell 
lines showing a decrease in the MTDH gene expression 
in colorectal cancer cell lines compared to non-cancerous 
cells lines (VH10, VH25, Hek293)
610 nm for Light Cycler® Yellow 555. Relative mRNA 
expression was calculated using the 2-ΔΔCt method. 
Results
MTDH gene expression was measured in cancer-
ous (Caco2, HT29, PC3, PC3M, PC3MLN4, PC3MPro) 
and non-cancerous cell lines (HEK293 and fibroblasts: 
VH10 and VH25) using quantitative qPCR. All results 
were performed three times in three biological replicates 
and normalized with PBGD expression. We observed 
a statistically significant decrease of MTDH expression 
in Caco2, HT29 and PC3 cells in comparison to fibro-
blasts. Furthermore, our analysis conducted in the 
PC3, Caco2 and non-cancerous cell lines HEK293 cell 
demonstrated levels of the MTDH gene expression 
similar to those reported by the HPA (Human Protein 
Atlas) project available online. 
The mean level of the MTDH mRNA expression, 
normalized in relation to the reference gene PBGD, 
increased in the prostate cancer cell lines as follows: 
PC3 (0.62 ± 0.07), PC3M (1.02 ± 0.17), PC3M-
Pro4 (1.20 ± 0.22), and reached the highest value in 
PC3M4 (1.86 ± 0.48). In VH10, the expression of this 
gene was at 1.0 ± 0.07 (Fig. 2). 
Discussion
Overexpression of MTDH gene was noticed in mul-
tiple cancers including colorectal cancer [13] breast 
cancer [14], prostate cancer [15] and glioma [16]. 
Katarzyna Kaminska et al., A preliminary study on MTDH expression as a potential prognostic cancer marker
213www.journals.viamedica.pl/medical_research_journal
between VH10 and Hek293, with was consistent with 
results of MTDH expression in cell lines derived from 
brain obtained in HPA.
Finally, we assessed whether the expression of 
MTDH increases with the progression of the disease. For 
this purpose, we used prostate cancer malignant trans-
formation model, cell lines derived from PC3 (PC3M, 
PC3MLN4 and PC3MPro4). The highest level of meta-
static capabilities in a mouse model of human prostate 
cancer reflects PC3MLN4. We found that this cell line 
showed the highest level of MTDH expression. We con-
firmed that metastatic capabilities of prostate cancer cell 
lines correlated with an increase of MTDH expression.
High expression of MTDH was also detected in the 
tissues and other cancer prostate cell lines. Kikuno 
[18] showed MTDH overexpression in clinical PC tissue 
samples and cultured PC cells compared to benign 
prostatic hyperplasia tissue samples and normal pros-
tate epithelial cells. They proposed MTDH as a novel 
genetic biomarker to serve as an attractive molecular 
target for new anticancer agents to prevent PC cell 
progression and metastasis. High MTDH expression 
also was observed in another prostate cancer cell lines: 
LNCaP, DU145 [18, 19]. 
In addition to gene expression evaluation — Mtdh 
protein level was measured using human prostate tissue 
microarray [15]. It showed that Mtdh distribution is in the 
cytoplasm and cell membrane and was concluded that 
subcellular distribution can predict Gleason grade and 
survival. Furthermore, Mtdh was also found in the bone 
metastases of prostate cancer (81.8%) [15]. Erdem et al. 
[20] examined 97 prostatectomy samples and showed 
that MTDH coupled with the main fibroblast growth 
factor is an independent prognostic parameter. These 
results suggest that MTDH expression, both on RNA and 
protein level seems to be a potential prognostic factor 
in prostate cancer. Moreover, the possible signalling 
pathways in prostate cancer cell lines, in which MTDH 
might be involved and that can be potential therapeutic 
targets for antineoplastic agents, have been studied. 
Inhibition of the Mtdh expression proved to be one of 
the molecular events demonstrating an antineoplastic 
effect [19]. In order to implement MTDH expression 
as a prognostic factor, further studies with consistent 
results are needed - gene expression analysis using 
digital droplet PCR and measurement of the potential 
biomarker in plasma or urine collected from prostate 
cancer’s patients - should also be taken into account.
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